In Germany, chemical giant BASF has partnered with Utah’s 3Helix Inc. to advance 3Helix’s short, single-stranded collagen-like peptides. The proteins have the ability to bind to damaged and denatured collagen, with applications in anti-aging and personal care.
The partnership comes after successful research and development work by 3Helix, which has progressed the patented CHP technology from laboratory to pilot stage. BASF plans to bring the technology in-house and launch initial CHP solutions in 2025.
The deal also involves an equity investment and licensing agreement, granting BASF exclusive rights to commercialize CHP solutions for the personal care field.
“3Helix’s results from laboratory trials are very encouraging and show the potential of this new innovation for the personal care market,” said Dr. Marina Safont Sempere, Director of New Business Models & Digital Officer, Care Chemicals at BASF.